Symptoms and severity of Crohn’s Disease and Ulcerative Colitis can vary greatly between individuals.
Researchers at the University of Cambridge School of Clinical Medicine have now identified a gene expression profile that can divide patients with CD and UC into two otherwise undistinguishable subgroups — those with a high incidence of treatment-nonresponsive, frequently relapsing, or chronically active disease and those with mild disease.
This could help doctors and patients better determine the kind of treatment they may wish to pursue. This could be especially relevant if you are concerned about choosing between more aggressive medical therapies and/or more holistic approaches.
Read the report here.
Eating SCD 
Hey Paul, thx so much for posting this. Fascinating stuff. I know they are doing a similar study right now at Stanford Immunology regarding immune suppressants and biological markers for Crohn’s patients. Not sure when its going to be concluded, but I’m guessing you’ll probably find it too. thx for posting! adam
Hey Adam,
You betcha. Thanks for the heads up on the Stanford study.
-Paul
Thanks for posting… This is pretty interesting, and very relevant to what I’m going through right now, as a recently diagnosed Crohn’s patient trying to choose among various treatments.
Damion,
You’re welcome.
FYI just in case your Dr. is unfamiliar with it, a drug called Naltrexone is being used in low doses by people with IBD. I have not used it myself, but many seem to get relief from it. I’ve written about it here and here.
You may also find some interest in this post.
-Paul